全球多重检测市场规模（按技术、最终用户、应用、地区、范围和预测）

多重检测的全球市场规模及预测

多重检测市场预计在 2024 年价值为 430 万美元，预计到 2031 年将达到 736 万美元，2024 年至 2031 年的复合年增长率为 7.66%。多重分析是生物医学研究和诊断领域的一种革命性方法，可以同时检测和量化单一样本中的多种分析物。这些检测方法因其能够加快处理速度、节省宝贵的样本量并提供对复杂生物系统的完整洞察而吸引了广泛关注和采用。多重分析使用微阵列、基于珠子的分析和微流体等现代技术同时分析各种生物标记物，包括蛋白质、核酸和代谢物。

这些检测通常用于研究参与发炎、免疫细胞活化和宿主-病原体相互作用的细胞激素、趋化因子和其他免疫介质。多重细胞激素检测，例如基于珠子的免疫检测和基于流式细胞仪的检测，可以同时检测生物样本中的多种细胞因子和趋化因子，为免疫系统功能、疾病病理生理学和治疗反应提供重要见解。这些检测方法对于自体免疫和传染病、癌症免疫学以及疫苗开发的研究和开发很有用。

多重侦测的全球市场动态

主要市场驱动因子

慢性病发生率不断上升：

慢性病，尤其是癌症和自体免疫疾病的日益流行，是多重检测市场发展的主要驱动力。根据世界卫生组织 (WHO) 的数据，癌症是世界第一大死亡原因，2020 年约有 1,000 万人死于癌症。国际癌症研究机构（IARC）预测，到2040年，全球癌症病例数将达到2,840万，比2020年增加47%。此疾病发生率的不断增加使得对有效诊断方法（例如多重检测）的需求不断增加。美国癌症协会报告称，用于评估癌症风险的多重基因组检测在 2019 年至 2023 年间将增加 30%，这表明这些技术正得到越来越广泛的应用。

蛋白质体学与基因体学研究的进展：

蛋白质体学和基因组学研究的重大进展推动了对多重检测的需求。据美国国家人类基因组研究所称，人类基因组定序成本已从 2001 年的 1 亿美元降至 2023 年的 1,000 美元以下，使基因组研究更加经济实惠。这导致需要多重测试的研究活动增加。根据2023年全球基因组学市场报告，基因组学市场预计从2023年到2030年将以13.6%的复合年增长率成长，到2030年达到629亿美元。此外，多重检测约占基因组学市场的 18%，显示具有巨大的成长潜力。

药物研发活动增加：

製药业对个人化医疗和标靶药物的日益重视，加速了多重测试在药物研发过程中的使用。据美国药物研究和製造商协会 (PhRMA) 称，2015 年至 2023 年间，正在开发的个人化药物数量将增加 145%。 2023年，美国食品药物管理局（FDA）将核准25种个人化药物，占所有新药核准的35%。这一趋势推动了多重测试的需求，这对于发现生物标记和理解复杂的生物途径至关重要。

主要问题

交叉反应性与特异性

：多重分析中最大的课题之一是保持每种分析物的特异性，同时限制不同目标之间的交叉反应。当检测中使用的抗体或探针非特异性地与不需要的标靶结合时，就会发生交叉反应，导致假阳性结果。对于含有许多不同浓度分析物的复杂生物样整体说，这尤其具有课题性。为了实现高特异性，必须仔细选择交叉反应性最小的抗体和探针，并且必须彻底优化测试条件以减少非特异性结合。

动态范围与灵敏度：

多重分析中的另一个课题是在较宽的动态分析范围内建立足够的灵敏度。生物样本中通常含有浓度跨越几个数量级的分析物，因此需要能够准确检测低丰度和高丰度目标的检测方法。然而，由于亲和力、检测效率和基质成分的干扰等因素的变化，在多重分析中保持所有分析物的一致灵敏度非常困难。

资料分析与解释

多重检测资料的分析和解释带来了新的课题，特别是在处理多个样本中检测到的多种分析物产生的大型资料集时。资料分析方法必须考虑分析物之间的复杂交互作用以及可能的批次效应、标准化问题和统计考量。此外，将多重检测数据与基因组学和蛋白​​质组学等其他组学数据集相结合将获得有用的见解并揭示与生理相关的模式和相关性，这需要先进的生物资讯工具和计算方法。

主要趋势

技术进步：

技术进步是推动多重测试进步的主要趋势之一。随着时间的推移，检测平台、检测方法和检测形式已经取得了显着的进步，从而提高了多重检测的灵敏度、特异性和通量。基于微阵列的分析、基于珠子的分析和微流体平台能够高度准确且有效地检测各种分析物，包括蛋白质、核酸和小分子。

个人化医疗的应用：

推动多重检测应用的另一个重要趋势是其在个人化医疗中的应用日益广泛。在疾病异质性和个人化治疗的必要性被广泛认可的时代，多重检测提供了一种有用的工具来识别患者特定的分子谱并指导个性化治疗。在肿瘤学中，多重测试用于分析恶性肿瘤的分子特征并找到与治疗反应和预后相关的特定生物标记。

整合多组学方法

：多组学方法的整合是影响多重测试领域的另一个显着趋势。多组学是对基因组学、转录组学、蛋白质组学、代谢组学和表观基因组学等多个分子层的全面探究，以全面瞭解生物系统。可以同时测量多个组学数据的多重检测方法正在迅速开发，以帮助理解复杂的生物过程和疾病。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况 市集亮点

第三章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

第 4 章 多重侦测市场（依技术划分）

基于蛋白质的多重检测
• 基于核酸的多重检测

第 5 章 多重侦测市场（依应用）

• 临床诊断
• 药物发现与开发
• 研究用途

第 6 章 多重侦测市场（依最终使用者划分）

• 医院和诊断实验室
• 製药和生技公司
• 学术和研究机构

第 7 章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 8 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 对市场的影响

第 9 章 竞争格局

• 大型公司
• 市占率分析

第十章 公司简介

• Thermo Fisher Scientific
• Bio-Rad Laboratories, Inc.
• Luminex Corporation
• QIAGEN N.V.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Abcam plc
• Randox Laboratories Ltd.
• Merck KGaA
• BD（Becton, Dickinson and Company）

第 11 章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 12 章附录

• 缩写列表
• 来源与参考文献

Global Multiplex Assays Market Size and Forecast

Multiplex Assays Market size was valued at USD 4.3 Million in 2024 and is projected to reach USD 7.36 Million by 2031 , growing at a CAGR of 7.66% from 2024 to 2031. Multiplex assays are a groundbreaking approach in biomedical research and diagnostics, allowing for the simultaneous detection and quantification of many analytes inside a single sample. These assays have received a lot of attention and adoption because of their capacity to expedite processes, save valuable sample volumes, and provide complete insights into complicated biological systems. Multiplex assays use modern technologies like microarrays, bead-based assays, and microfluidics to analyze a variety of biomarkers simultaneously including proteins, nucleic acids, and metabolites.

These assays are commonly used to study cytokines, chemokines, and other immune mediators involved in inflammation, immune cell activation, and host-pathogen interactions. Multiplex cytokine assays such as bead-based immunoassays and flow cytometry-based assays allow for the simultaneous detection of numerous cytokines and chemokines in biological samples yielding crucial insights into immune system function, disease pathophysiology, and treatment responses. These assays are useful in the research of autoimmune and infectious disorders, cancer immunology, and vaccine development, all of which involve dysregulated immune responses.

Global Multiplex Assays Market Dynamics

The key market dynamics that are shaping the multiplex assays market include:

Key Market Drivers:

Increasing Prevalence of Chronic Diseases:

The increased prevalence of chronic diseases, particularly cancer and autoimmune disorders, is a key driver of the multiplex assays market. According to the World Health Organization (WHO), cancer is the biggest cause of death worldwide, accounting for approximately 10 million deaths in 2020. The International Agency for Research on Cancer (IARC) predicts that the worldwide cancer burden will reach 28.4 million cases by 2040, up 47% from 2020. The rising illness load raises the need for effective diagnostic methods such as multiplex tests. The American Cancer Society states that multiplex gene panel testing for cancer risk assessment grew by 30% between 2019 and 2023, indicating that these technologies are becoming more widely used.

Advancements in Proteomics and Genomics Research:

The tremendous advancement in proteomics and genomics research is driving the demand for multiplex assays. The National Human Genome Research Institute claims that the cost of sequencing a human genome has dropped from USD 100 Million in 2001 to less than $1,000 in 2023, making genomic research more accessible. This has increased research activities needing multiplex tests. According to the Global Genomics Market Report 2023, the genomics market is predicted to develop at a 13.6% CAGR between 2023 and 2030, reaching USD 62.9 Billion by 2030. The research also mentions that multiplex assays account for roughly 18% of the genomics market, indicating a huge growth potential.

Increasing Drug Discovery and Development Activities:

The pharmaceutical industry's rising emphasis on personalized medicine and targeted medicines is accelerating the use of multiplex tests in drug research and development processes. According to PhRMA, the number of personalized medications in development surged by 145% between 2015 and 2023. In 2023, the US Food and Drug Administration (FDA) authorized 25 customized medicines, accounting for 35% of all new drug approvals. This trend is driving up the need for multiplex tests, which are critical for discovering biomarkers and comprehending complex biological pathways.

Key Challenges:

Cross-Reactivity and Specificity

: One of the most difficult aspects of multiplex assays is maintaining acceptable specificity for each analyte while limiting cross-reactivity between distinct targets. Cross-reactivity occurs when antibodies or probes employed in an assay bind non-specifically to unwanted targets resulting in false positive results. This can be especially challenging in complicated biological samples containing many analytes at different concentrations. To achieve high specificity, carefully choose antibodies or probes with minimum cross-reactivity and thoroughly optimize test conditions to reduce non-specific binding.

Dynamic Range and Sensitivity:

Another problem in multiplex assays is establishing adequate sensitivity over a wide dynamic range of analytic values. Biological samples frequently contain analytes with concentrations ranging several orders of magnitude necessitating assays capable of accurately detecting both low and high abundance targets. However, maintaining consistent sensitivity for all analytes in a multiplex assay can be difficult because of variances in affinity, detection efficiency, and interference from matrix components.

Data Analysis and Interpretation:

Analyzing and interpreting multiplex assay data poses a new difficulty especially when dealing with huge datasets derived from several analytes detected across multiple samples. Data analysis methods must take into account the intricate interactions between analytes as well as possible batch effects normalization concerns, and statistical considerations. Furthermore, combining multiplex assay data with other omics datasets such as genomics or proteomics necessitates advanced bioinformatics tools and computational methodologies to extract useful insights and find physiologically significant patterns or correlations.

Key Trends:

Advancements in Technology:

Technological advancements are one of the key trends driving the progress of multiplex tests. Assay platforms, detection methods, and assay formats have advanced significantly over time increasing the sensitivity, specificity, and throughput of multiplex assays. Microarray-based assays, bead-based assays, and microfluidic platforms have allowed for the very precise and efficient detection of a wide range of analytes including proteins, nucleic acids, and tiny molecules.

Application in Personalized Medicine:

Another important trend driving the adoption of multiplex assays is their growing use in personalized medicine. Multiplex assays provide a useful tool for identifying patient-specific molecular profiles and guiding tailored treatments as illness heterogeneity and the need for individualized treatment methods are becoming more widely recognized. In oncology, multiplex tests are used to molecularly profile malignancies to find particular biomarkers linked with therapy response and prognosis.

Integration of Multi-Omics Approaches

: The incorporation of multi-omics techniques is another notable trend impacting the field of multiplex tests. Multi-omics is the complete investigation of several molecular layers such as genomes, transcriptomics, proteomics, metabolomics, and epigenomics to achieve a holistic understanding of biological systems. Multiplex assays which allow for the simultaneous measurement of various omics data types are rapidly being created to help understand the complexities of biological processes and diseases.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Multiplex Assays Market Regional Analysis

Here is a more detailed regional analysis of the multiplex assays market:

North America:

According to Verified Market Research, North America is expected to dominate the multiplex assays market during the forecast period. North America, particularly the United States, has a high prevalence of chronic diseases, which drives the demand for multiplex assays in diagnostics and research. According to the Centers for Disease Control and Prevention (CDC), six out of every ten persons in the United States have a chronic disease, with four out of ten having two or more. The American Cancer Society predicts that there will be 1.9 million new cancer cases identified in the United States by 2024. According to the National Cancer Institute, the usage of multiplex gene panel testing in cancer diagnosis grew by 35% from 2020 to 2023, with over 1.2 million tests performed in 2023 alone. High illness burden and rising usage of modern diagnostic technologies contribute considerably to the region's dominance in the multiplex assays market.

Furthermore, North America leads in life sciences research and development, which drives demand for advanced research tools such as multiplex assays. The National Institutes of Health's (NIH) budget for fiscal year 2024 is USD 47.5 Billion, up USD 2.5 Billion from 2023. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the US biopharmaceutical industry invested USD 102.3 Billion in R&D in 2023, with a large chunk going into genomics and proteomics research, which significantly relies on multiplex assays.

Asia Pacific:

The Asia Pacific region is expected to experience a significant increase in revenue growth within the global multiplex assays market during the forecast period. The Asia Pacific region is experiencing a large increase in chronic diseases, which is increasing demand for improved diagnostic tools such as multiplex assays. According to the World Health Organization (WHO), non-communicable illnesses account for 71% of all fatalities in Southeast Asia. According to the International Diabetes Federation, the number of adults with diabetes in the Asia-Pacific region is anticipated to rise by 30%, from 163 million in 2019 to 212 million in 2045. In China alone, the National Cancer Center reported 4.5 million new cancer cases in 2023, representing a 5% rise over the previous year. The increased illness burden is driving the use of multiplex tests for early detection and monitoring of numerous disorders at the same time.

Furthermore, the Asia Pacific region is experiencing rapid expansion of healthcare infrastructure and increased healthcare spending, which is driving up the usage of modern diagnostic technology. According to the World Bank, health expenditure as a proportion of GDP in East Asia and the Pacific has risen from 6.6% in 2010 to 7.2% in 2022. In India, the government allotted ₹89,155 crore (about USD 11 Billion) for the healthcare sector in the 2023-2024 budget, up 13% from the previous year.

Global Multiplex Assays Market: Segmentation Analysis

The Multiplex Assays Market is segmented based on Technology, End-User, Application and Geography.

Multiplex Assays Market, By Technology

• Protein-based Multiplex Assays
• Nucleic Acid-based Multiplex Assays

Based on Technology, the Multiplex Assays Market is divided into Protein-based Multiplex Assays and Nucleic Acid-based Multiplex Assays. The nucleic acid-based multiplex assay segment is estimated to hold a prominent position within the market. This is primarily due to the versatility and sensitivity of nucleic acid detection methods such as polymerase chain reaction (PCR), reverse transcription PCR (RT-PCR), and nucleic acid microarrays.

Multiplex Assays Market, By End-User

• Hospitals and Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

Based on End-User, the Multiplex Assays Market is divided into Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Academic & Research Institutes. The pharmaceutical & biotechnology companies segment is estimated to dominate the multiplex assays market. These companies heavily rely on multiplex assays for various stages of drug discovery, preclinical and clinical development as well as biomarker validation. The demand from pharmaceutical and biotechnology companies stems from the imperative to conduct comprehensive and high-throughput screening of potential drug candidates, evaluate their efficacy and safety profiles, and identify relevant biomarkers for patient stratification and therapeutic response monitoring.

Multiplex Assays Market, By Application

• Clinical Diagnostics
• Drug Discovery and Development
• Research Applications

Based on Application, the Multiplex Assays Market is divided into Clinical Diagnostics, Drug Discovery & Development, and Research Applications. The clinical diagnostics segment is estimated to dominate the market due to the growing demand for accurate and quick diagnostic procedures that can assess several biomarkers from a single sample. Clinical diagnostics applications are essential for disease identification and monitoring, especially in chronic and infectious disorders. Multiplex assays' capacity to efficiently give comprehensive results makes them indispensable instruments in modern healthcare, consolidating their market leadership.

Multiplex Assays Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Multiplex Assays Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate the multiplex assays market. The presence of key industry players, continuous technical advancements, and substantial healthcare expenditures collectively contribute to its prominence. North America's robust healthcare infrastructure coupled with a well-established regulatory framework fosters innovation and facilitates market penetration for multiplex assays. Additionally, the region's proactive approach to healthcare delivery emphasis on precision medicine, and strong research and development ecosystem further bolster its market dominance.

Key Players

• The Multiplex Assays study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., Luminex Corporation, QIAGEN N.V., Agilent Technologies, Inc., Illumina, Inc., Abcam plc, Randox Laboratories Ltd., Merck KGaA, BD (Becton, Dickinson and Company)

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Multiplex Assays Market Recent Developments
• In May 2022, CellCarta, a global precision medicine laboratory services provider, acquired the commercial rights to Precision tests' antibody panels and tests. Precision Assays is a leader in next-generation targeted proteomics testing. Precision tests provides pharmaceutical and biotech companies with advanced multiplex quantitative immuno-MRM mass spectrometry-based tests.
• In June 2023, Bio-Techne Corporation, a worldwide life sciences business, acquired Lunaphore, Inc, a leading provider of fully automated spatial biology solutions. The acquisition will support the development of diagnostic tools, streamline clinical trials, and eventually enhance patient outcomes.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Multiplex Assays Market, By Technology

• Protein-based Multiplex Assays
• Nucleic Acid-based Multiplex Assays

5. Multiplex Assays Market, By Application

• Clinical Diagnostics
• Drug Discovery and Development
• Research Applications

6. Multiplex Assays Market, By End User

• Hospitals and Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Thermo Fisher Scientific
• Bio-Rad Laboratories, Inc.
• Luminex Corporation
• QIAGEN N.V.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Abcam plc
• Randox Laboratories Ltd.
• Merck KGaA
• BD (Becton, Dickinson and Company)

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References